Α-Galactosidase: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
Line 30: Line 30:


{{pharmacology-stub}}
{{pharmacology-stub}}
== Α-Galactosidase ==
<gallery>
File:3a5v.jpg|Α-Galactosidase
File:Reaction mechanism for human α-GAL.png|Α-Galactosidase
File:MEL.jpg|Α-Galactosidase
</gallery>

Latest revision as of 00:35, 20 February 2025

Α-Galactosidase is an enzyme that hydrolyzes terminal, non-reducing α-D-galactose residues in α-D-galactosides, including substrates like melibiose, raffinose, and stachyose. It is encoded by the GLA gene in humans.

Function[edit]

Α-Galactosidase is a glycoside hydrolase involved in the breakdown of certain complex carbohydrates. It catalyzes the removal of terminal α-galactose residues, a critical step in the metabolism of certain oligosaccharides and glycolipids.

Clinical significance[edit]

Deficiency of α-Galactosidase is linked to Fabry disease, a rare genetic disorder characterized by a buildup of a particular type of fat in the body's cells. This can lead to a wide range of symptoms, including pain, skin rashes, kidney problems, and heart disease.

Therapeutic use[edit]

Recombinant human α-Galactosidase, marketed as Agalsidase beta and Agalsidase alfa, is used as an enzyme replacement therapy for Fabry disease.

See also[edit]

References[edit]

<references />

External links[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Α-Galactosidase[edit]